Adjuvant RSV Vaccine in Older Adults

Opinion
Video

Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.

  1. While the follow-up data for the AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?
    1. Efficacy of preventing RSV-related lower respiratory tract disease
    2. Adverse effects
    3. Trial limitations
Recent Videos
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
1 KOL is featured in this program
Carrie Koenigsfeld, PharmD, FAPhA, an expert on RSV vaccination
Carrie Koenigsfeld, PharmD, FAPhA, an expert on RSV vaccination
1 KOL is featured in this program
1 KOL is featured in this program
1 KOL is featured in this series.
1 KOL is featured in this series.
Ashley Pugh, PharmD, and Lauren Angelo, PharmD, MBA